Developing Innovative Pharmaceutical Products

Pharma Two B is clinical-stage pharmaceutical company developing novel, synergistic, combination products based on previously approved drugs. The Company established a platform for identification, characterization and development of low dose combinations that seek to offer high therapeutic effects with improved safety profiles, that would lead to clinically and commercially added value products. The combinations are aimed for the 505(b)(2) approval pathway allowing a shorter regulatory process to registration. The Company’s lead product in development, P2B001is a low dose, sustained release combination of Pramipexole and Rasagiline and is currently in phase III clinical trial, as a novel treatment for early-stage Parkinson’s Disease (PD). Data from P2B001 phase II clinical trial implies that it may provide significant therapeutic effects comparable to those published for higher doses of the individual components, with favorable safety profile. Further studies with P2B001 in advanced PD patients’ population are planned.

Leadership:

Investing partner / fund: